DORM
Dorman Products, Inc.
DORM's outlook is improving, though it still trails on the overall score.
NKE
NIKE, Inc.
NKE has a slight edge over DORM overall, supported by stronger valuation and stronger fundamentals.
DORM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
DORM's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
DORM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $132 | — |
| Cheap | 19x | $125 | -5.6% |
| Current | 20x | $132 | — |
| Fair | 23x | $152 | +15% |
| Expensive | 28x | $191 | +45% |
Historical ranges are pointers, not guarantees.
DORM's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE has the edge over DORM in the historical PE scenario, which offers more potential upside but is not a forecast.
DORM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
DORM has the edge over NKE on the outlook, with more favorable valuation and earnings expectations.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
DORM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.63 | +28% |
| Q3 2026 | $6.72 | -16% |
| Q2 2026 | $7.22 | -1.6% |
| Q1 2026 | $6.20 | -11% |
| Q4 2025 | $6.64 | +8.1% |
| Q3 2025 | $8.02 | +34% |
| Q2 2025 | $7.34 | +34% |
| Q1 2025 | $6.96 | +40% |
| Q4 2024 | $6.14 | +50% |
DORM has the edge over NKE on earnings, with more consistent year-over-year improvement.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
DORM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $561.7M | +3.3% |
| Q2 2026 | $544.6M | +0.7% |
| Q1 2026 | $528.8M | +4.2% |
| Q4 2025 | $537.9M | +0.8% |
| Q3 2025 | $543.7M | +7.9% |
| Q2 2025 | $541M | +7.6% |
| Q1 2025 | $507.7M | +8.3% |
| Q4 2024 | $533.8M | +8% |
DORM has the edge over NKE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -4.7 points |
| Q2 2026 | 21% | +6.1 points |
| Q1 2026 | 11% | -4.7 points |
| Q4 2025 | 5.8% | -10 points |
| Q3 2025 | 19% | +3.7 points |
| Q2 2025 | 15% | +0.8 points |
| Q1 2025 | 16% | +4.2 points |
| Q4 2024 | 16% | +0.6 points |
DORM has the edge over NKE on profitability, with a higher operating margin.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE's operating margin was 8.2% last quarter, about level with the same quarter a year ago.
DORM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $56.9M | +3022% |
| Q2 2026 | $143.5M | +146376% |
| Q1 2026 | $35.3M | -12% |
| Q4 2025 | $33.5M | -47% |
| Q3 2025 | $1.8M | -95% |
| Q2 2025 | $98K | -100% |
| Q1 2025 | $40.3M | -2.4% |
| Q4 2024 | $63.2M | +30% |
DORM has the edge over NKE on cash flow, with more consistent year-over-year improvement.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
DORM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -135K shares |
| 1 year | -3% | -922K shares |
| 3 years | -5.4% | -1.7M shares |
| 5 years | -6.2% | -2M shares |
| Available history | -8.7% | -2.8M shares |
DORM has the edge over NKE on shareholder dilution, with a more favorable share count trend.
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has 1.5B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
DORM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
DORM's net debt is less than a year of its operating earnings (EBITDA).
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE has the edge over DORM on leverage, with a lower net debt burden relative to earnings.
DORM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.7 | Neutral |
| Stochastic | 49.5 | Neutral |
DORM's weekly RSI is 54 (neutral) and its Stochastic is 50 (neutral).
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
DORM PE vs Consumer Cyclical Sector
| Metric | DORM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 18x | 9% above |
| PE % | 24 | 47 | 23 pts below |
DORM is trading at 20x earnings, in line with the Consumer Cyclical sector's median of 18x.
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE has the edge over DORM on valuation relative to its sector.
DORM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $127.7 | 3.4% above |
| 20 week MA | $131.3 | 0.5% above |
| 50 week MA | $124.6 | 5.9% above |
| 100 week MA | $128.6 | 2.7% above |
| 200 week MA | $110.3 | 20% above |
DORM has the edge over NKE on trend strength, trading above more of its moving averages.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
DORM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.1 | $89.6 | +19% |
| 2021 | $89.6 | $106.4 | +19% |
| 2022 | $106.4 | $81.3 | -24% |
| 2023 | $81.3 | $83.4 | +2.6% |
| 2024 | $83.4 | $132.2 | +58% |
| 2025 | $132.2 | $126.6 | -4.2% |
| 2026 YTD | $126.6 | $132.0 | +4.2% |
DORM has the edge over NKE on returns for 2026, with the stronger performance.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has finished four years in a row lower, and it's down 38% so far in 2026.